Talphera ACRX Stock
Talphera Price Chart
Talphera ACRX Financial and Trading Overview
Talphera stock price | 0.86 USD |
Previous Close | 1.21 USD |
Open | 1.23 USD |
Bid | 0 USD x 1000 |
Ask | 0 USD x 3200 |
Day's Range | 1.21 - 1.34 USD |
52 Week Range | 0.55 - 7.6 USD |
Volume | 111.83K USD |
Avg. Volume | 177.83K USD |
Market Cap | 13.55M USD |
Beta (5Y Monthly) | 0.192253 |
PE Ratio (TTM) | 0.19682539 |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4 USD |
ACRX Valuation Measures
Enterprise Value | 3.45M USD |
Trailing P/E | 0.19682539 |
Forward P/E | -0.75151515 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 7.6488605 |
Price/Book (mrq) | 0.9509202 |
Enterprise Value/Revenue | 1.95 |
Enterprise Value/EBITDA | -0.113 |
Trading Information
Talphera Stock Price History
Beta (5Y Monthly) | 0.192253 |
52-Week Change | -70.47% |
S&P500 52-Week Change | 20.43% |
52 Week High | 7.6 USD |
52 Week Low | 0.55 USD |
50-Day Moving Average | 0.84 USD |
200-Day Moving Average | 2.18 USD |
ACRX Share Statistics
Avg. Volume (3 month) | 177.83K USD |
Avg. Daily Volume (10-Days) | 177.58K USD |
Shares Outstanding | 10.92M |
Float | 10.81M |
Short Ratio | 6.39 |
% Held by Insiders | 1.05% |
% Held by Institutions | 13.43% |
Shares Short | 859.97K |
Short % of Float | 7.93% |
Short % of Shares Outstanding | 7.87% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 2419.59% |
Operating Margin (ttm) | -1811.23% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -40.80% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 1.77M USD |
Revenue Per Share (ttm) | 0.21 USD |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -30424000 USD |
Net Income Avi to Common (ttm) | 41.58M USD |
Diluted EPS (ttm) | 6.3 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 13.35M USD |
Total Cash Per Share (mrq) | 1.22 USD |
Total Debt (mrq) | 3.37M USD |
Total Debt/Equity (mrq) | 23.66 USD |
Current Ratio (mrq) | 1.834 |
Book Value Per Share (mrq) | 1.304 |
Cash Flow Statement
Operating Cash Flow (ttm) | -24647000 USD |
Levered Free Cash Flow (ttm) | -18001376 USD |
Profile of Talphera
Country | United States |
State | CA |
City | Hayward |
Address | 25821 Industrial Boulevard |
ZIP | 94545 |
Phone | (650) 216-3500 |
Website | https://www.acelrx.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | 19 |
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and ARX-03, which is in Phase 2 clinical trial for the treatment of procedural anxiety and acute pain. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company also develops Fedsyra, an ephedrine pre-filled syringe that contains 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection; and phenylephrine, a phenylephrine pre-filled syringe, which contains 10 ml of a solution of 50 mcg/ml phenylephrine for injection. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Hayward, California.
Q&A For Talphera Stock
What is a current ACRX stock price?
Talphera ACRX stock price today per share is 0.86 USD.
How to purchase Talphera stock?
You can buy ACRX shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Talphera?
The stock symbol or ticker of Talphera is ACRX.
Which industry does the Talphera company belong to?
The Talphera industry is Drug Manufacturers-Specialty & Generic.
How many shares does Talphera have in circulation?
The max supply of Talphera shares is 16.95M.
What is Talphera Price to Earnings Ratio (PE Ratio)?
Talphera PE Ratio is 0.00000000 now.
What was Talphera earnings per share over the trailing 12 months (TTM)?
Talphera EPS is 0 USD over the trailing 12 months.
Which sector does the Talphera company belong to?
The Talphera sector is Healthcare.
Talphera ACRX included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
NASDAQ Global Market Composite NQGM | 1647.83 USD — |
-5.17
|
— — | 1610.28 USD — | 1681.06 USD — | — - | — — |
NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 19079.55 USD — |
-5.82
|
— — | 19064.73 USD — | 19740.96 USD — | — - | — — |
- {{ link.label }} {{link}}